FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 397 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... April 13, 2023 Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive... April 25, 2022 OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... September 6, 2023 New Study Finds Dogs Can Sniff Out Lung Cancer — And... April 10, 2019 Load more HOT NEWS Opinion: “There’s cause for optimism in 2021 and beyond” FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-mutated Metastatic... Daughter And Her Terminally Ill Dad Go On Bucket List Adventures... Hero Nanny Permanently Injured While Saving 2-Year-Old From Speeding Car About...
